Omalizumab

Omalizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IgE Fc region
Clinical data
Pronunciation	/ˌoʊməˈlɪzumæb/; OH-mə-LI-zoo-mab
Trade names	Xolair
AHFS/Drugs.com	Monograph
MedlinePlus	a603031
License data	EU EMA: by INN; US DailyMed: Omalizumab;
Pregnancy; category	AU: B1;
Routes of; administration	Subcutaneous
ATC code	R03DX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	26 days
Identifiers
CAS Number	242138-07-4 ;
DrugBank	DB00043 ;
ChemSpider	none;
UNII	2P471X1Z11;
KEGG	D05251;
ChEMBL	ChEMBL1201589 ;
Chemical and physical data
Formula	C6450H9916N1714O2023S38
Molar mass	145058.53 g·mol−1
	(what is this?) (verify)

Omalizumab, sold under the brand name Xolair, is a medication to treat asthma, nasal polyps, and urticaria (hives).

Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.